Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

 

International Congress of Parkinson’s Disease and Movement Disorders ®

Congress

Therapeutic Plenary Session 1104

Atypical Parkinsonism

Sunday, October 4, 2026
16:00 - 17:30 | Grand Ballroom, Level 1

In this session, the faculty will provide updates on treatment strategies and emerging therapeutic targets for the management of patients with progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), encompassing both pharmacological and non-pharmacological treatments

Chairs:

Beomseok Jeon, Korea
Claudia Trenkwalder, Germany

Presenters:

Therapeutic Frontiers in Progressive Supranuclear Palsy
Huw Morris, United Kingdom

Multiple System Atrophy: Current Therapy and Emerging Targets
Junghwan Shin, Korea

Non-Pharmacological Interventions for Parkinsonism
Jori Fleisher, USA

CSPC Liaison(s):

Chin-Hsien Lin, Taiwan

Learning Objectives

At the conclusion of this session, participants should be better able to:

  1. Identify symptomatic treatments and the latest therapeutic developments in PSP
  2. Identify the symptomatic treatments and the latest therapeutic developments in MSA
  3. Summarize the multimodal, technology-assisted, and other non-pharmacological management strategies for patients with PSP and MSA

Recommended Audience

Clinician / General Neurology
Fellow / Resident / Student
Health Professional (non-physician)
Industry

Education Level

Beginner / Foundational
Intermediate / Experienced